Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Phosphoinositide 3-kinase (PI3K)-Akt-mammalian Target of Rapamycin (mTOR) pathway is crucial in cell growth and survival.
• Dysregulation of this pathway is implicated in various cancers, including follicular lymphoma and breast cancer.
• Targeting this pathway presents a promising strategy for cancer therapy.

Purpose of the Study:

• To summarize recent research on dual PI3K/mTOR inhibitors.
• To review their structure-activity relationships, pharmacokinetics, and clinical applications.
• To evaluate their potential as effective cancer therapeutics.

Main Methods:

• Review of recent scientific literature on PI3K/mTOR dual inhibitors.
• Analysis of structure-activity relationships (SAR) for enhanced potency.
• Examination of pharmacokinetic profiles and clinical trial data.

Main Results:

• Dual PI3K/mTOR inhibitors demonstrate higher potency and efficacy compared to single-target inhibitors.
• These inhibitors effectively suppress cancer cell proliferation and induce apoptosis.
• Low doses exhibit significant anti-cancer effects with reduced drug resistance.

Conclusions:

• Dual PI3K/mTOR inhibitors represent a promising class of targeted cancer drugs.
• Their favorable potency, low resistance, and broad applicability warrant further clinical investigation.
• Continued research into SAR and clinical practice will optimize their therapeutic use.